Influenza B/Victoria Antigen Induces Strong Recall of B/Yamagata But Lower B/Victoria Response in Children Primed With Two Doses of B/Yamagata

被引:50
作者
Skowronski, Danuta M. [1 ,2 ]
Hottes, Travis S. [1 ]
De Serres, Gaston [3 ]
Ward, Brian J. [4 ]
Janjua, Naveed Z. [1 ,2 ]
Sabaiduc, Suzana [1 ]
Chan, Tracy [1 ]
Petric, Martin [1 ]
机构
[1] British Columbia Ctr Dis Control, Vancouver, BC, Canada
[2] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada
[3] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada
[4] McGill Univ, Montreal Gen Hosp, Vaccine Res Unit, Hlth Ctr MUHC, Montreal, PQ H3G 1A4, Canada
关键词
influenza; influenza vaccine; immunology; children; infants; child; influenza vaccines/immunology; influenza vaccines/administration and dosage; B VIRUS; VACCINE;
D O I
10.1097/INF.0b013e31822db4dc
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: Trivalent inactivated influenza vaccine (TIV) contains 1 of 2 influenza B/lineages (B/Yamagata or B/Victoria) annually. We assessed prime-boost responses in young children following a change in the B/lineage included in TIV. Methods: Participants were primed during a clinical trial as infants or toddlers with two 0.25 or two 0.5 mL doses of 2008-2009 TIV containing B/Florida/4/06(Yamagata) antigen. In subsequent years, sequential subsets received annual age-appropriate doses of 2009-2010 and 2010-2011 TIV containing the changed influenza B/lineage antigen (B/Brisbane/60/08(Victoria)). Serologic response was assessed pre- and postimmunization by hemagglutination inhibition (HI; with/without ether treatment of influenza B antigen) and microneutralization. The primary immunogenicity outcome was the seroprotection rate (SPR) measured by HI without ether treatment (SPR:HI titers >= 40). Results: Fifty-six children were included in 2009-2010 and 36 in 2010-2011 analyses. Before the 2009-2010 TIV dose, antibody to all 2008-2009 TIV components had fallen to low levels: SPR < 10% for B/Florida/4/06(Yamagata) and B/Brisbane/60/08(Victoria) antigens. A single 2009-2010 TIV dose boosted antibody to the shared 2008-2009/2009-2010 influenza A antigens and to the priming 2008-2009 B/Florida/4/06(Yamagata) antigen with SPRs > 85%. In contrast, antibody to the B/Brisbane/60/08(Victoria) antigen included in the 2009-2010 TIV remained low: SPR < 25%. Antibody to the B/Brisbane/60/08(Victoria) antigen was not improved from a further dose in the 2010-2011 TIV: SPR 31% versus SPR 69% to B/Yamagata. A similar pattern of B/Yamagata dominance was observed when III testing was conducted with antigen prepared by ether treatment. Conclusions: Repeated annual TIV doses containing B/Victoria-lineage antigen strongly recalled antibodies to the B/Yamagata antigen of first exposure, but elicited lower B/Victoria responses.
引用
收藏
页码:833 / 839
页数:7
相关论文
共 22 条
  • [1] The need for quadrivalent vaccine against seasonal influenza
    Belshe, Robert B.
    [J]. VACCINE, 2010, 28 : D45 - D53
  • [2] *CPMP, 1997, CPMPBWP21496, P1
  • [3] Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers
    Englund, Janet A.
    Walter, Emmanuel B.
    Gbadebo, Adepeju
    Monto, Arnold S.
    Zhu, Yuwei
    Neuzil, Kathleen M.
    [J]. PEDIATRICS, 2006, 118 (03) : E579 - E585
  • [4] Mazurek Gerald H., 2010, Morbidity and Mortality Weekly Report, V59, P1
  • [5] Karber G., 1931, ARCH EXP PATH PHARMA, V162, P480, DOI DOI 10.1007/BF01863914
  • [6] INCREASED SENSITIVITY AND REDUCED SPECIFICITY OF HEMAGGLUTINATION INHIBITION TESTS WITH ETHER-TREATED INFLUENZA-B SINGAPORE/222 79
    KENDAL, AP
    CATE, TR
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1983, 18 (04) : 930 - 934
  • [7] Original Antigenic Sin Responses to Influenza Viruses
    Kim, Jin Hyang
    Skountzou, Ioanna
    Compans, Richard
    Jacob, Joshy
    [J]. JOURNAL OF IMMUNOLOGY, 2009, 183 (05) : 3294 - 3301
  • [8] CROSS-REACTIVE ANTIBODIES INDUCED BY A MONOVALENT INFLUENZA-B VIRUS-VACCINE
    LEVANDOWSKI, RA
    GROSS, PA
    WEKSLER, M
    STATON, E
    WILLIAMS, MS
    BONELLI, J
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1991, 29 (07) : 1530 - 1532
  • [9] ETHER TREATMENT OF TYPE-B INFLUENZA-VIRUS ANTIGEN FOR THE HEMAGGLUTINATION INHIBITION TEST
    MONTO, AS
    MAASSAB, HF
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1981, 13 (01) : 54 - 57
  • [10] The Wages of Original Antigenic Sin
    Morens, David M.
    Burke, Donald S.
    Halstead, Scott B.
    [J]. EMERGING INFECTIOUS DISEASES, 2010, 16 (06) : 1023 - 1024